FDA’s Call on Migraine Drug Could Be Trouble for Teva

Shares of Teva Pharmaceuticals weakened after
Credit Suisse downgraded the stock ahead of an FDA decision on Fremanezumab, a key migraine drug. …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.